top of page

GynOnco Group | Ginecología Oncológica en Puerto Rico | Cuidado Experto y Compasivo"

Search

A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Resp

GynOnco Group Team
Aug 16, 2025
1 min read

STUDY ID: NCT06580314

STATUS: Enrolling

CONDITION: Ovarian Cancer

SPONSOR: NRG Oncology

FOR MORE INFORMATION VISIT: https://www.clinicaltrials.gov/study/NCT06580314

Recent Posts

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NRG-GY019)

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NRG-GY019)

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (RAINFOL-02)

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (RAINFOL-02)

bottom of page